NFE2L2 and multiple sclerosis: Recently published results regarding the role of Nrf2 in other models of SSc and the use of DMF in pulmonary arterial hypertension models strongly confirm our observations and, along with ours, brings major data to strongly support the use of DMF to ameliorate the clinical symptoms of SSc, as the molecule has already been approved by the FDA in multiple sclerosis and psoriasis (27, 42, 43).